Common side effects of combination artemether/lumefantrine therapy in adults include headache, anorexia, dizziness, and asthenia. Common side effects in children include pyrexia, cough, vomiting, anorexia, and headache. Possible serious adverse effects include QT prolongation, bullous eruption, urticaria, splenomegaly (9%), hepatomegaly (adults, 9%; children, 6%), hypersensitivty reaction, and angioedema.
Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Pyrimethamine | The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Lumefantrine. |
| Dapsone | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Lumefantrine. |
| Mefloquine | The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Lumefantrine. |
| Quinine | The risk or severity of QTc prolongation can be increased when Quinine is combined with Lumefantrine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Lumefantrine. |
| Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Lumefantrine. |
| Quinidine | The risk or severity of QTc prolongation can be increased when Quinidine is combined with Lumefantrine. |
| Primaquine | The risk or severity of QTc prolongation can be increased when Primaquine is combined with Lumefantrine. |
| Quinacrine | The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Lumefantrine. |
| Atovaquone | The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Lumefantrine. |
| Proguanil | The risk or severity of QTc prolongation can be increased when Proguanil is combined with Lumefantrine. |
| Sulfadoxine | The risk or severity of QTc prolongation can be increased when Sulfadoxine is combined with Lumefantrine. |
| Hydroxychloroquine | The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lumefantrine. |
| Tafenoquine | The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Lumefantrine. |
| Artesunate | The risk or severity of QTc prolongation can be increased when Artesunate is combined with Lumefantrine. |
| Artenimol | The risk or severity of QTc prolongation can be increased when Artenimol is combined with Lumefantrine. |
| Artefenomel | The risk or severity of QTc prolongation can be increased when Artefenomel is combined with Lumefantrine. |
| Chlorproguanil | The risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Lumefantrine. |
| Mizoribine | The risk or severity of QTc prolongation can be increased when Mizoribine is combined with Lumefantrine. |
| Pyronaridine | The risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Lumefantrine. |
| Artemisinin | The risk or severity of QTc prolongation can be increased when Artemisinin is combined with Lumefantrine. |
| Artemotil | The risk or severity of QTc prolongation can be increased when Artemotil is combined with Lumefantrine. |
| Piperaquine | The risk or severity of QTc prolongation can be increased when Piperaquine is combined with Lumefantrine. |
| Tetrandrine | The risk or severity of QTc prolongation can be increased when Tetrandrine is combined with Lumefantrine. |
| Cycloguanil | The risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Lumefantrine. |
| Brexpiprazole | The metabolism of Brexpiprazole can be decreased when combined with Lumefantrine. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Lumefantrine. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Lumefantrine. |
| Halofantrine | Lumefantrine may increase the QTc-prolonging activities of Halofantrine. |
| Thiethylperazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Thiethylperazine. |
| Triflupromazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Triflupromazine. |
| Fluphenazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Fluphenazine. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Moricizine. |
| Trifluoperazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Trifluoperazine. |
| Acetophenazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Acetophenazine. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Alimemazine. |
| Periciazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Periciazine. |
| Acepromazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Acepromazine. |
| Aceprometazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Aceprometazine. |
| Thioproperazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Thioproperazine. |
| BL-1020 | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with BL-1020. |
| Cyamemazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Cyamemazine. |
| Propiopromazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Propiopromazine. |
| Perazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Perazine. |
| Butaperazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Butaperazine. |
| Chlorproethazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Chlorproethazine. |
| Thiazinam | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Thiazinam. |
| Dixyrazine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Dixyrazine. |
| Perphenazine enanthate | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Perphenazine enanthate. |
| St. John's Wort | The serum concentration of Lumefantrine can be decreased when it is combined with St. John's Wort. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lumefantrine. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lumefantrine. |
| Erythromycin | The serum concentration of Lumefantrine can be increased when it is combined with Erythromycin. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Lumefantrine. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lumefantrine. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Lumefantrine. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Lumefantrine. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Lumefantrine. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Lumefantrine. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Lumefantrine. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lumefantrine. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Lumefantrine. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Lumefantrine. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Lumefantrine. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Lumefantrine. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Lumefantrine. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Lumefantrine. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Lumefantrine. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Lumefantrine. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Lumefantrine. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Lumefantrine. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Lumefantrine. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Lumefantrine. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Lumefantrine. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Lumefantrine. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lumefantrine. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Lumefantrine. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Lumefantrine. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Lumefantrine. |
| Mibefradil | The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Lumefantrine. |
| Probucol | The risk or severity of QTc prolongation can be increased when Probucol is combined with Lumefantrine. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Lumefantrine. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Lumefantrine. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Lumefantrine. |
| Azimilide | The risk or severity of QTc prolongation can be increased when Azimilide is combined with Lumefantrine. |
| Pracinostat | The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Lumefantrine. |
| Technetium Tc-99m ciprofloxacin | The risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Lumefantrine. |
| Garenoxacin | The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Lumefantrine. |
| Tedisamil | The risk or severity of QTc prolongation can be increased when Tedisamil is combined with Lumefantrine. |
| Tucidinostat | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Lumefantrine. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Telavancin is combined with Lumefantrine. |
| Nemonoxacin | The risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Lumefantrine. |
| Nilvadipine | The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Lumefantrine. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Antazoline is combined with Lumefantrine. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Bedaquiline. |
| Fendiline | The risk or severity of QTc prolongation can be increased when Fendiline is combined with Lumefantrine. |
| Eperisone | The risk or severity of QTc prolongation can be increased when Eperisone is combined with Lumefantrine. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Lumefantrine. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Lumefantrine. |
| Melperone | The risk or severity of QTc prolongation can be increased when Melperone is combined with Lumefantrine. |